

## **Auswahl an Publikationen von Prof. Schmidt-Wolf zum Schwerpunkt Stammzelltransplantation:**

1. Schmidt-Wolf I, Brandhorst D, Hertenstein C, Wetter O. Results with a modified human myeloma stem cell assay. *Klin Wochenschr* 61:1101-1103 (1983)
2. Aihara M, Aihara Y, Schmidt -Wolf G, Schmidt-Wolf IGH, Sikic BI, Blume KG, Chao NJ. A combined approach for purging multidrug resistant leukemic cell lines in bone marrow, using a monoclonal antibody and chemotherapy. *Blood* 77(9):2079 - 2084 (1991)
3. Schmidt-Wolf IGH, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse / human lymphoma model to evaluate cytokine-induced killer cells with potent anti-tumor cell activity. *J Exp Med* 174(1):139-149 (1991; cited in *Science* 259:1463 (1993))
4. Schmidt-Wolf IGH, Aihara M, Negrin RS, Blume KG, Chao NJ. In vitro and in vivo activity of murine lymphokine-activated killer cells after cryopreservation. *Transfusion* 32(1):42-45 (1992)
5. Schlegel PG, Schmidt-Wolf G, Schmidt-Wolf IGH, Kwak LW, Chao NJ. Lymphokine-activated killer cell activity against autologous lymphoma cells following bone marrow transplantation. *Cancer Research, Therapy and Control* Vol.3:145 -152 (1993)
6. Schmidt-Wolf IGH, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS. Phenotypic characterization and identification of effector cells involved in tumor recognition of cytokine-induced killer cells. *Experimental Hematology* 21:1673-1679 (1993)
7. Schmidt-Wolf IGH, Dejbakhsh-Jones S, Ginzton N, Greenberg P, Strober S. T cell subsets and suppressor cells in human bone marrow. *Blood*, 80(12):3242 -3250 (1992)
8. Schmidt-Wolf IGH, Liang O, Dejbakhsh-Jones S, Wang H, Cheng L, Holm B, Bell R, Strober S. Homogeneous antigen receptor beta chain genes in cloned CD4+ - CD8+ - alpha, beta+ T suppressor cells. *J Immunol.* 151:5348-5353 (1993)
9. Schmidt-Wolf IGH, Schwerdtfeger R, Schwella N, Gallardo J, Schmid H, Huhn D, Siegert W. Diffuse pulmonary alveolar hemorrhage after allogeneic bone marrow transplantation. *Ann Hematol*, 67:139-141 (1993)
10. Schwella N, Schwerdtfeger R, Schmidt-Wolf I, Schmid H, Siegert W. Pneumococcal arthritis after allogeneic bone marrow transplantation. *Bone Marrow Transplantation* 12:165-166 (1993)
11. Schwella N, Koenig V, Schwerdtfeger R, Schmidt-Wolf I, Schmid H, Riess H, Siegert W. Ondansetron for efficient emesis control during total body irradiation. *Bone Marrow Transplantation* 13, 169-171 (1994)
12. Schmidt-Wolf IGH, Lefterova P, Johnston V, Neubauer A, Huhn D, Negrin R, Blume KG. Propagation of T cells with NK cell marker. *Br J Haematol* 87, 453-458 (1994)
13. Schwella N, Schwerdtfeger R, Koenig V, Blasczyk R, Schmid H, Schmidt -Wolf I, Henze G, Siegert W. Allogeneic bone marrow transplantation for recurrence of leukemia after autologous bone marrow transplantation. *Transplantation* 57, 1263-1265 (1994)
14. Schmidt-Wolf IGH, Neubauer A, Finke S, Csipai M, Wittig B, Huhn D. Interleukin-7 gene therapy for patients with metastatic colon cancer, renal cell cancer, malignant melanoma or lymphoma. *Human Gene Ther* 5(9), 1161-1168 and 1197 (1994)
15. Schmidt-Wolf G, Schmidt-Wolf I. Human cancer and gene therapy. *Ann Hematol* 69(6), 273-279 (1994)

16. Scheffold C, Brandt K, Johnston V, Lefterova P, Huhn D, Neubauer A, Negrin RS, Schmidt-Wolf IGH. Potential of autologous cytokine induced killer cells for bone marrow purging in patients with chronic myeloid leukemia. *Bone Marrow Transplantation* 15, 33-39 (1995)
17. Schmidt -Wolf G, Schmidt-Wolf IGH. Cytokines and gene therapy. *Immunol Today* 16(4), 173-175 (1995)
18. Schmidt-Wolf GD, Schmidt-Wolf IGH. Bone marrow and clinical gene therapy. *J Hematother* 4, 551-561 (1995)
19. Scheffold C, Schöttker B, Lefterova P, Csipai M, Glasmacher A, Huhn D, Neubauer A, Schmidt-Wolf IGH. Increased sensitivity of myeloid leukemia cell lines: Potential of lovastatin as a bone marrow purging agent. *Acta Haematol* 104(2-3):72-79 (2000)
20. Ziske C, Gorschlüter M, Mey U, Offergeld R, Glasmacher A, Schmidt-Wolf IGH. Sequential high-dose chemotherapy with autologous stem cell support in patients with limited-stage small cell lung cancer. *Anticancer Research* 22 (6) 3723-3726 (2002)
21. Abken H, Hombach A, Reinhard G, Märten A, Schlimper C, Glasmacher A, Bieber T, Schmidt-Wolf IGH. Cellular immunotherapy after autologous hematopoietic stem cell transplantation: Experimental strategies and clinical experiences. *Leukemia & Lymphoma* 44(4): 583-592 (2003)
22. Ziske C, Mezger J, Jiménez C, Kleinschmidt R, Pels H, Schlegel U, Schmidt-Wolf IGH. High dose chemotherapy with autologous peripheral blood stem cell support in an adult patient with a recurrent AFP-producing intracranial germinoma. *German Medical Science Vol.1, Doc03, 20030701* (2003)
23. Gorschlüter M, Mey U, Glasmacher A, Schwerdtfeger R, Schmidt-Wolf IGH. Acute myeloid leukemia with near-triploid karyotype and extramedullary involvement of mediastinum. *Bone Marrow Transplant* 36(12):1107 (2005)
24. Breitkreutz I, Lokhorst HM, Raab MS, van der Holt BV, Cremer FW, Herrmann D, Glasmacher A, Schmidt-Wolf IGH, Blau IW, Martin H, Salwender H, Hänel A, Sonneveld P, Goldschmidt H. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide on peripheral blood stem cell collection yield. *Leukemia* 1-6, 2007 Mar 22
25. Mey UJM, Jha V, Strehl JW, Gorschlüter M, Rabe C, Hoebert E, Popp H, Schmidt-Wolf IGH. High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma. *GMS* 5:2007
26. Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, Salwender H, Blau IW, Weisel K, Pfreundschuh M, Scheid C, Dührsen U, Lindemann W, Schmidt-Wolf IG, Peter N, Teschendorf C, Martin H, Haenel M, Derigs HG, Raab MS, Ho AD, van de Velde H, Hose D, Sonneveld P, Goldschmidt H. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. *Blood*. 2012 Jan 26;119(4):940-8. doi: 10.1182/blood-2011-09-379164.
27. Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Hänel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. *Haematologica*. 2014 Jan;99(1):148-54. doi: 10.3324/haematol.2013.087585.